Garrigues acts for Qiagen on €118m STAT-Dx acquisition
Garrigues advised Qiagen on the acquisition of STAT-Dx, a Spanish healthcare company that develops diagnostics for analysing diseases and infections.
The deal was valued at €118 million, according to Mergermarket.
A Qiagen statement said: “The acquisition is expected to be completed in the second quarter of 2018 and funded from existing cash reserves.”
STAT-Dx has developed a system, to be branded QIAstat-Dx, that enables processing of up to 48 molecular targets simultaneously to diagnose syndromes such as serious respiratory or gastrointestinal infections.
In 2018, sales of about $7 million are expected from the QIAstat-Dx launch in “Europe and other markets”, while sales of at least $30 million are expected in 2019, the Qiagen statement said.
